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SINDROM METABOLIK DAN PERKAITANNYA DENGAN ADIPONEKTIN, 
VITAMIN D DAN AKTIVITI FIZIKAL DALAM KALANGAN ORANG 
DEWASA DI SEBUAH INSTITUSI PENGAJIAN TINGGI DI EMIRIAH ARAB 
BERSATU 
ABSTRAK 
 
 Sindrom metabolik (MetS) adalah kelompok faktor risiko penyakit 
kardiovaskular dan diabetes jenis 2. Ia dikaitkan dengan disfungsi tisu adipos akibat dari 
obesiti, satu fenomena global berkaitan gaya hidup yang sedang meningkat. Sementara 
itu, hypovitaminosis D semakin mendapat perhatian selain kesan klasik pada tulang.  
Faktor gaya hidup, biokimia dan genetik dihipotesis untuk menyumbang kepada 
patofisiologi MetS . Tujuan kajian ini adalah untuk mengkaji hubungan MetS dan 
komponennya dengan adiponektin, vitamin D, polimorfisme gen VDR, dan aktiviti 
fizikal. Kajian ini telah dijalankan dari tahun 2012 hingga 2015 dalam 2 fasa (P-1 dan P-
2). P-1 (keratan rentas): Seramai 235 orang dewasa (64 lelaki dan 171 wanita) dari 
komuniti Universiti Sharjah telah diambil menyertai kajian. Pengukuran antropometri, 
ujian biokimia (glukosa, insulin, profil lipid, vitamin D dan HMW adiponektin) dan 
analisis genetik (untuk polimorfisme gen VDR: Taqii, FokI, dan BsmI) telah dijalankan. 
Profil demografi, pengambilan diet (kekerapan makanan semi-kuantitatif) dan persepsi 
senaman (skala faedah Senaman / halangan) telah digunakan. P-2 (intervensi): Seramia 
52 peserta wanita memakai pedometers untuk 9 minggu selepas sesi pendidikan  dengan 
matlamat untuk mencapai 10,000 langkah setiap hari. Semua parameter asas telah dinilai 
semula selepas intervensi. Prevalens Sindrom metabolik adalah 17.5%; lebih tinggi pada 
xviii 
 
lelaki (OR = 10.97, 95% CI: 5.1-23.61, p <0.001) dan orang dewasa berumur 40 tahun 
ke atas (OR = 9.59, 95% CI: 3.98-23.1, p <0.001). HMW adiponektin adalah lebih tinggi 
dalam kalangan wanita dan mereka yang tidak mempunyai MetS ; ia berkait secara 
langsung dengan HDL-kolesterol dan berkait secara songsang dengan ukuran obesiti dan 
tekanan darah. Tahap Vitamin D adalah 22.49 (19.6) nmol/L dan hanya 9.8% 
mempunyai tahap yang optimum. Vitamin D adalah lebih rendah secara ketara pada 
wanita [26.6 (13.58) nmol/L vs 34.03 (21.34) nmol/L, p <0.001] dan peserta tanpa MetS  
[29.6 (18.75) nmol/L vs 21.06 (19.1) nmol/L, p <0.001] berbanding peserta lain. 
Kejadian MetS adalah bebas daripada status vitamin D (OR = 1.78, 95% CI: 0.65-4.84, p 
= 0.25). Tiga reseptor polimorfisma gen vitamin D tidak menunjukkan hubungan dengan 
Sindrom metabolik. Walau bagaimanapun, polimorfisme Foki dan allele F pada wanita 
dikaitkan dengan tekanan darah sistolik lebih tinggi. Peserta melaporkan nisbah persepsi 
faedah / halangan latihan pada nilai 1.48. Peserta berjalan sebanyak 7056 ± 1570 
langkah setiap hari, mencatatkan peningkatan marginal pada akhir minggu ke 9. 
Pengurangan kecil tetapi ketara diperolehi dalam hampir semua parameter antropometri 
dan LDL-kolesterol (63.8 ± 18.04 mg/dl vs 59.17 ± 18.61 mg/dl; p = 0.01), manakala 
peningkatan sebanyak HMW adiponektin (4.08 ± 0.55 μg / ml vs 4.15 ± 0.53 μg / ml; p 
= 0.03) diperolehi. Hubungan songsang antara bilangan langkah dan pengukuran obesiti, 
dan hubungan positif dengan tahap HMW adiponektin telah dilihat dengan nyata. 
Walaupun bilangan langkah dalam kalangan  peserta indeks jisim tubuh (IJT) normal 
adalah lebih tinggi (7488.49 ± 1098) daripada peserta yang lebih tinggi IJT (6739.18 ± 
1793), bagaimanapun, peningkatan yang ketara dicatatkan pada lebih banyak varibel  
komposisi badan dalam peserta dengan IJT lebih tinggi berbanding peserta yang 
mempunyai BMI normal . Begitu juga dengan peningkatan yang ketara dalam profil 
xix 
 
biokimia diperolehi dalam peserta dengan IJT tinggi sahaja pada nilai trigliserida (71.62 
± 29.22 – 62.50 ± 29.16 mg/dl, p = 0.003) dan tahap insulin (21.7 ± 8,33-18,64 ± 8.25 
μU/L, p = 0.046) dan peningkatan dalam HMW adiponectin (3.77 ± 0.46 – 3.80 ± 0.44 
μg/ml, p = 0.034). Kesimpulannya, prevalen MetS adalah 17.5%, yang lebih ketara pada 
lelaki. HMW adiponektin boleh memainkan peranan dalam kejadian MetS  manakala 
vitamin D dan polimorfisme gen VDR boleh menjejaskan komponen MetS. Para peserta 
terdiri daripada "rendah aktif", walaupun berpersepsi lebih banyak manfaat senaman 
daripada halangan. Peningkatan nominal yang minima dalam aktiviti fizikal boleh 
memodulasi ukuran obesiti, HMW adiponektin dan profil lipid yang seterusnya 
mengurangkan risiko kardiovaskular, terutama dalam kalangan individu yang berlebihan 
berat badan/obes. 
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METABOLIC SYNDROME AND ITS RELATIONSHIPS WITH 
ADIPONECTIN, VITAMIN D AND PHYSICAL ACTIVITY AMONG ADULTS 
IN AN INSTITUTE OF HIGHER LEARNING IN THE UNITED ARAB 
EMIRATES 
ABSTRACT 
Metabolic syndrome (MetS) is a cluster of risk factors for cardiovascular disease 
and type 2 diabetes. It is associated with adipose tissue dysfunction resulting from 
obesity, an escalating global phenomenon related to lifestyle. Meanwhile, 
hypovitaminosis D is gaining attention beyond the classical effects on the skeleton. 
Lifestyle, biochemical and genetic factors are hypothesized to contribute to the 
pathophysiology of MetS. The aim of this study was to examine the relationships of 
MetS and its components with adiponectin, vitamin D, VDR gene polymorphisms, and 
physical activity. The study was conducted from year 2012 until year 2015 in 2 phases 
(P-1 and P-2). P-1 (cross-sectional):  A total of 235 adults (64 males and 171 females) 
from the University of Sharjah community were recruited. Anthropometric measures, 
biochemical tests (glucose, insulin, lipid profile, vitamin D and HMW adiponectin) and 
genetic analyses (for VDR gene polymorphisms: TaqI, FokI, and BsmI) were performed. 
Demographic profile, habitual dietary intake and exercise perception (Exercise 
benefits/barriers Scale) were used accordingly. P-2 (interventional): A total of 52 female 
participants wore pedometers for 9 weeks after an educational session and goal setting of 
10,000 steps per day. All baseline parameters were reassessed post-intervention. The 
prevalence of MetS was 17.5%; higher in males (OR=10.97, 95%CI: 5.1-23.61, p < 
0.001) and adults above 40 years old (OR=9.59, 95%CI: 3.98-23.1, p < 0.001). HMW 
adiponectin was higher in females and in those without MetS; being directly correlated 
with HDL-cholesterol and inversely correlated with obesity measures and blood 
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pressure. Vitamin D level was 22.49(19.6) nmol/L and only 9.8% had an optimal level. 
Vitamin D was significantly lower in females [26.6(13.58) nmol/L vs. 34.03(21.34) 
nmol/L, p < 0.001] and in those without MetS [29.6(18.75) nmol/L vs. 21.06(19.1) 
nmol/L, p < 0.001] than their counterparts. MetS occurrence was independent of vitamin 
D status (OR=1.78, 95%CI: 0.65-4.84, p=0.25). The three vitamin D receptor gene 
polymorphisms did not show any relationship with MetS. However, FokI 
polymorphisms and F allele in females were associated with higher systolic blood 
pressure. The participants reported exercise perception benefit/barrier ratio of 1.48. The 
participants walked 7056±1570 steps per day, recording a marginal increase toward the 
end of week 9. Small, though, significant reductions were noted in almost all 
anthropometric parameters and LDL-cholesterol (63.8±18.04 mg/dl vs. 59.17±18.61 
mg/dl; p=0.01), while an increase of HMW adiponectin (4.08±0.55 µg/ml vs. 4.15±0.53 
µg/ml; p = 0.03) was obtained. An inverse relationship between the number of steps and 
obesity measures, and positive relation with HMW adiponectin level were evident. 
While the number of steps in normal body mass index (BMI) participants was 
marginally higher (7488.49±1098) than those with higher BMI (6739.18±1793), 
however, significant improvement was recorded in more measures of body composition 
variables in participants with higher BMI than those with normal BMI. Similarly, 
significant improvement in biochemical profiles were observed in participants with high 
BMI on the level of triglycerides (71.62±29.22 to 62.50±29.16 mg/dl, p=0.003) and 
insulin levels (21.7±8.33 to 18.64±8.25 µU/l, p=0.046) and increase in HMW 
adiponectin (3.77±0.46 to 3.80±0.44 µg/ml, p=0.034).  In conclusion, the prevalence of 
MetS was 17.5%, being more common in males. HMW adiponectin could play a role in 
the development of MetS while vitamin D and VDR gene polymorphisms could affect 
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the components of MetS. The participants were “low active”, though perceived more 
benefits of exercise than barriers. Minimum nominal increase in physical activity can 
modulate obesity measure, HMW adiponectin and lipid profile with a possible 
subsequent decrease of cardiovascular risks, particularly in overweight/obese 
individuals.  
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
Overweight and obesity are becoming major global health problems, which may 
look like an unstoppable phenomenon. Worldwide, more than one billion adults are 
overweight and 500 million are obese (World Obesity Organization, n.d.). They 
predispose to non-communicable diseases (NCDs), which include cardiovascular 
diseases, stroke, type 2 diabetes mellitus and certain types of cancer. These NCDs cause 
massive human loss through disabling and killing people in their productive ages i.e. 
premature death (before they reach the age of 70 years) (WHO, 2015). Despite the 
global efforts for the prevention of NCDs, they are still the leading causes of death in 
many countries (Beaglehole et al., 2011). Around 2.2 million die each year from NCDs 
in countries of the Eastern Mediterranean Region and without effective steps, it is 
expected that this number will reach to 4 million in 2030 (WHO, 2015). The latest 
Global Status Report on non-communicable diseases of the World Health Organization 
(WHO) indicated that smoking, alcohol consumption, obesity, low physical activity, 
elevated blood pressure and dyslipidemia are important risk factors for NCDs in which 
cardiovascular diseases and type 2 diabetes mellitus make most of the load (World 
Health Organization, 2014). 
The United Arab Emirates is one of the countries of the Eastern Mediterranean 
Region (WHO, n.d.). It is one of the rapidly developing countries (Gardner and 
Howarth, 2009) and it became a modern and wealthy country with a Western lifestyle. 
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The country comprises of a multinational population with a variety of educational 
backgrounds, religious beliefs and cultural practices (Loney et al., 2013). In the United  
 
 
 
 
 
 
 
 
Arab Emirates, lifestyle changes have been the highlight of debate during the last 
decades. High incomes with increased consumption of fast food including sugar loaded 
drinks combined with low levels of physical activity have put the United Arab Emirates 
population at high risk for obesity and its related co-morbidities (Loney et al., 2013). 
Recently, a screening program called “Weqaya” has been launched in the United Arab 
Emirates. It is a screening program for the health status of individuals in order to provide 
a proper follow up in the event of being affected by or at risk of developing 
cardiovascular disease and diabetes or having the risk factors associated with these 
preventable diseases (Health Authority of Abu Dhabi, n.d.). Results from Weqaya 
showed that the risk factor prevalence rates were as follows: obesity, 35%; overweight, 
Figure 1.1  Probability of dying from the four main non-communicable diseases 
between the ages of 30 and 70 years, comparable estimates, 2012 (World Health 
Organization, 2014) 
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32%; central obesity, 55% (Hajat et al., 2012). This rapidly increasing incidence of 
obesity is associated with 37% and 4% of total deaths because of cardiovascular diseases 
and type 2 diabetes mellitus respectively (World Health Organization, 2014).  
Metabolic syndrome is a bunch of risk factors for the development of 
cardiovascular diseases and type 2 diabetes mellitus of metabolic origin (“Third Report 
of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III) final report.,” 2002). Typically, metabolic syndrome includes a group of components 
such as obesity, high blood pressure, high blood sugar, and dyslipidemia. Other risk 
factors for the development of metabolic syndrome include increasing age, changes in 
the levels of male, female and stress hormones, physical inactivity and genetic 
predisposition (MedlinePlus, n.d.). However, metabolic syndrome is not a new concept, 
but it has received a lot of attention in the past few years probably because of the high 
prevalence of cardiovascular diseases and type 2 diabetes mellitus.  
Obesity, which is an important component of metabolic syndrome, is marked by 
excessive accumulation of fat in the adipose tissue. Currently, adipose tissue is widely 
accepted as an active and dynamic tissue with endocrine functions (Kershaw and Flier, 
2004; Scherer, 2006) rather than just a storage depot. Recent progress in the research 
about the metabolic properties of the adipose tissue and the discovery of its ability to 
produce biologically active molecules known as “adipocytokines, is rebuilding the 
concepts about adipose tissue biology and opens the gate to study the role of adipose 
tissue in metabolic syndrome. 
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The adipocytokines are produced by the adipocytes and macrophages of the 
adipose tissue and are engaged in many physiological and pathophysiological processes 
(Rasouli and Kern, 2008). In obesity, there is an alteration in the metabolic and 
endocrine functions of adipose tissue that leads to a change in the levels of the 
adipocytokines. Hence, the adipocytokines are proposed to be important determinants of 
obesity associated complications such as insulin resistance (Xu et al., 2003), type 2 
diabetes mellitus (Rajkovic et al., 2014)`and atherogenic dyslipidemia (Ha et al., 2014). 
Also, the adipocytokines were suggested to be involved in hypertension, cardiovascular 
diseases (Hubert et al., 1983) and certain types of cancers (Calle et al., 2003). Examples 
of the adipocytokines are adiponectin, leptin, resistin, tumor necrosis factor-alpha (TNF-
α), interleukin-6 (IL-6), angiotensinogen and plasminogen activator inhibitor-1 (PAI-1) 
and many more. 
Adiponectin is the most abundant and relatively new adipocytokine that is 
exclusively secreted by the adipocytes (Scherer et al., 1995). It exhibits insulin-
sensitizing, fat-burning (Yamauchi et al., 2001), anti-atherogenic (Shimada et al., 2004) 
and anti-inflammatory properties (Ouchi et al., 2003). It is distinct from other 
adipocytokines in that adipose tissue production and circulating level of adiponectin is 
decreased with obesity. In addition, low level of adiponectin in healthy individuals is 
linked to increased risk of cardiovascular events (Pischon et al., 2004). The levels of 
adiponectin were found to be affected by genetic factors (Yamamoto et al., 2002), 
ethnicity (Martin et al., 2008; Pereira et al., 2011), dietary fat content (Barnea et al., 
2006), exercise (Lee et al., 2013) and drugs (Li et al., 2010; von Eynatten et al., 2009). 
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Vitamin D, vitamin D receptor (VDR) and the necessary enzymes which are 
engaged in the formation of the biologically active form of vitamin D [1,25(OH)2D], 
play an important role in the vitamin D endocrine system. This system is well known as 
a key player for the normal development and mineralization of a healthy skeleton. Non-
classic effects of low level of vitamin D is being potentially associated with many 
conditions including hypertension, type 2 diabetes mellitus, common cancers and 
autoimmune diseases (Demay, 2006). Meanwhile, vitamin D deficiency has been 
identified as a pandemic and worldwide health problem, especially in the United Arab 
Emirates due to infrequent exposure to sunlight because of a change in the lifestyle of 
the local population (Al Anouti et al., 2011). Hence, vitamin D status may be related to 
metabolic syndrome development. 
The increasing prevalence of obesity has been in part attributed to the changes in 
the lifestyle; dietary factors and physical activity patterns. Current evidence suggests 
that the increase in the prevalence of obesity occurs after or at the same time of decrease 
in physical activity (Wareham et al., 2005). Thus, physical activity was suggested to 
counteract the development of obesity and could improve the risk factors for 
cardiovascular diseases and type 2 diabetes mellitus and metabolic syndrome in turn. 
Moreover, physical activity can improve cardiorespiratory fitness with subsequent 
reduction of death from cardiovascular events, in another word being physically active 
may decrease the burden and hazard of obesity (Lee et al., 1999). Despite the known 
benefits of physical activity, still, there is a significant decrease in the level of physical 
activity which includes every day occupation-related (Church et al., 2011) and 
household management physical activity (Archer et al., 2013). This decline in energy 
expenditure substantially contributes to the increase of body weights for men and 
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women, and the Global Status Report (2014) indicates that the prevalence of insufficient 
physical activity in adults from the United Arab Emirates aged 18 years and over is 
38.4% which necessitates an urgent interference (World Health Organization, 2014). 
Nevertheless, in order to plan an effective physical activity promotion programs, 
sufficient evidence of individuals’ attitudes toward engagement in physical activity 
program is required. So far, only one study has examined barriers towards physical 
activity in patients with type 2 diabetes mellitus in the United Arab Emirates (Al-Kaabi 
et al., 2009). Therefore, it is important to explore how the individuals perceive the 
benefits and barriers to exercise.  
1.2 Statement of Problem 
Based on this background, it seems that the simultaneous increase in the 
prevalence of obesity, low level of physical activity and low blood levels of adiponectin 
and vitamin D, could contribute to the pathophysiology of metabolic syndrome. 
Since the mid of the 1970s, the prevalence of obesity and its related disorders 
have increased in the population of the United Arab Emirates, with a subsequent 
increase in premature mortality. People who were obese and physically inactive with 
reduced vitamin D level and adiponectin were more prone to have metabolic syndrome.  
In recent decades, many researchers showed interest in studying different aspects 
of metabolic syndrome. These include prevalence and incidence of metabolic syndrome 
and risks that lead to the development of other conditions such as type 2 diabetes 
mellitus, cardiovascular diseases, and stroke in an attempt to have a better understanding 
of the pathophysiology of development of the syndrome. Early identification of the risk 
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factors among adults from the United Arab Emirates may be useful in the improvement 
of the conditions associated with metabolic syndrome. 
The best available treatment of metabolic syndrome is to prevent its occurrence 
by modification of the lifestyle, followed by identification and treatment of individual 
risk factors of metabolic syndrome in young population so as to prevent the development 
of cardiovascular diseases and type 2 diabetes mellitus with their complications later in 
life.  
In spite of all the efforts in the understanding of metabolic syndrome, its risk 
factors and the possible management and its epidemiology among adults from the 
United Arab Emirates are largely indefinite. This study aimed at illustrating the 
prevalence and risk factors of metabolic syndrome among study population from the 
United Arab Emirates.  
1.3 Objectives 
1.3.1 General Objective 
The objectives of this study were to examine the relationships of metabolic 
syndrome and its components with high molecular weight (HMW) adiponectin, vitamin 
D, and VDR gene polymorphisms, and to explore the effect of minimal physical activity 
on metabolic syndrome components. 
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1.3.2 Specific Objective 
1. To determine the prevalence of metabolic syndrome and its individual 
components in adults from the United Arab Emirates using the International 
Diabetes Federation (IDF) criteria for the diagnosis of metabolic syndrome. 
2. To investigating the relationships between high molecular weight adiponectin 
with the metabolic syndrome and its components in adults from the University of 
Sharjah, United Arab Emirates. 
3. To assess the vitamin D status and to investigate the associations of vitamin D 
with metabolic syndrome and its components in adults from the University of 
Sharjah, United Arab Emirates. 
4. To determine the associations between three (FokI, TaqI and BsmI) VDR gene 
polymorphisms and metabolic syndrome and its components in Arab adults from 
the University of Sharjah, United Arab Emirates. 
5. To examine the perceived exercise benefits and barriers of adults from the 
University of Sharjah, United Arab Emirates using the Exercise Benefits/Barriers 
Scale (EBBS) questionnaire. 
6. To examine the effects of steps counts (using pedometers) on metabolic 
syndrome components and HMW Adiponectin. Also, to compare the effect of 
steps counts in lean and overweight/obese participants. 
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1.4 Research questions 
i. What is the prevalence of metabolic syndrome and its individual components in 
adults from the University of Sharjah, United Arab Emirates using the 
International Diabetes Federation (IDF) criteria for the diagnosis of metabolic 
syndrome?  
ii. What are the relationships between high molecular weight adiponectin with the 
metabolic syndrome and its components in adults from the University of Sharjah, 
United Arab Emirates?  
iii. What is the status of vitamin D in the study population? 
iv. Is there any association between vitamin D and metabolic syndrome and its 
components? 
v. Is there any association between three (FokI, TaqI and BsmI) VDR gene 
polymorphisms and metabolic syndrome and its components in Arab adults from 
the University of Sharjah, United Arab Emirates?  
vi. How adults from the University of Sharjah, United Arab Emirates perceive the 
exercise benefits and barriers?  
vii. What are the effects of steps counts on metabolic syndrome components and 
HMW Adiponectin? 
viii. Do steps counts have different effects in lean and overweight/obese participants? 
1.5 Research Hypothesis 
Ha: HMW adiponectin, vitamin D, and physical activity are associated with 
metabolic syndrome. 
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1.6 Significance of study 
 
The findings of this study will have a direct influence on different stakeholders. 
For researchers, the data will add value to the pool of scientific evidence regarding the 
epidemiological aspects of metabolic syndrome in terms of obesity, insulin resistance, 
hypertension and lipid profiles amongst healthy young adults (population section with 
lesser health priorities) residing in the UAE. The insight on the differential analysis of 
metabolically healthy v/s metabolically unhealthy adults sheds new light on their body 
constitutional differences and association with metabolic syndrome. The focus on 
nutritional status, biochemical profiles and effect of physical activity will uncover 
important links of vitamin D, adiponectin and physical activity with metabolic syndrome 
components in young adults.  
The translation of the results of this research will have an important bearing on 
the community, at large. The health policy makers will be able to emphasize on lifestyle 
improvement through promoting healthy diets and moderate physical activity as the 
mainstay of prevention strategies for metabolic syndrome. The role of vitamin D, in 
particular, in the health of the young adults will be addressed.  
1.7 Conceptual framework 
 
Figure 1.2 shows the possible mechanism of development of metabolic 
syndrome. The bad dietary habits together with the decrease in the levels of physical 
activity and genetic susceptibility contribute to increasing body weight i.e. 
overweight/obesity. The increase in body weight is mainly due to the accumulation of 
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excess fat particularly around the waist (central obesity), which is associated with 
adipose tissue dysfunction and decrease the bioavailability of vitamin D.  
Adipose tissue dysfunction is characterized by increase production of almost all 
adipocytokines with the exception of adiponectin that shows reduced level with obesity. 
This is together with reduced serum levels of vitamin D can result in inflammation, 
which affects organs involved in the insulin sensitivity such as liver, skeletal muscles 
and adipose tissue and ultimately leads to insulin resistance. 
Insulin resistance with its prominent feature of high serum levels of insulin could 
be the starting point in the development of the components of metabolic syndrome 
(atherogenic dyslipidemia, hyperglycemia, and hypertension) and eventually the 
metabolic syndrome with the increased risk of development cardiovascular disease and 
type 2 diabetes mellitus. 
  
12 
 
 
 
 
  
High calorie diet Lack of physical activity Genetic susceptibility 
Increase body weight 
Adipose tissue dysfunction 
Adiponectin,     Leptin, other adipocytokines and Inflammatory markers 
Inflammation and 
Insulin Resistance 
Hyperinsulinemia 
Elevated blood pressure 
Dyslipidemia 
Dysglycemia 
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CHAPTER 2 
REVIEW OF LITERATURE 
 
Metabolic syndrome has been described as a cluster of inter-related risk factors, 
the etiology of which is multifaceted (Reaven, 1988). The syndrome ultimately increases 
the risk of development of diabetes mellitus and cardiovascular diseases. This review is 
trying to shed light on the history, definitions, prevalence, and pathophysiology of 
metabolic syndrome and also to report what have been studied so far in relation to 
adiponectin, vitamin D, and physical activity. 
2.1 Metabolic Syndrome 
2.1.1 Metabolic syndrome definition and diagnostic criteria 
In fact, as early as the 1920s Kylin (1923) reported the association of high blood 
glucose, high blood pressure, and high serum uric acid in certain groups of patients(as 
cited in Oladejo, 2011, p. 78). In 1947, Vague found that upper body obesity (android or 
male pattern) was associated with diabetes mellitus and cardiovascular diseases in 
contrast to the lower body obesity (gynecoid pattern)(as cited in Hanley & 
Wagenknecht, 2008, p. 1153). Afterward, Avogaro et al (1967) added obesity and 
hyperlipidemia to the three features described by Kylin (as cited in Haffner & 
Taegtmeyer, 2003, p. 1541). Haller (1977) used the term “metabolic syndrome” for 
patients having obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia and 
hepatic steatosis. In addition to these risk factors, he reported that there is an increase of 
14 
 
blood viscosity with disturbances of coagulation that further increase risk of 
development of arteriosclerosis (Haller, 1977).  
Later, Reaven (1988) suggested that insulin resistance and the consequent 
hyperinsulinemia could clarify the mechanism of the clustering phenomenon of the risk 
factors and he named it as “syndrome X” (Reaven, 1988). Ferrannini et al (1991) 
reported similar clustering of interrelated abnormalities (decreased insulin sensitivity, 
glucose intolerance, elevated blood pressure, increased body fat mass and distribution, 
and dyslipidemia) and concluded that insulin resistance underlined each and all of the 
abnormalities. Hence “insulin resistance syndrome” was proposed to be the suitable term 
for such clustering (Ferranniniet al., 1991).  
In 1998, the World Health Organization (WHO) suggested the first definition of 
metabolic syndrome and in 1999 the WHO proposed the criteria of metabolic syndrome, 
which mandates the presence of insulin resistance for the diagnosis of metabolic 
syndrome. Accordingly, the diagnosis of metabolic syndrome can be made if there is 
type 2 diabetes mellitus, impaired fasting glucose (IFG), impaired glucose tolerance 
(IGT) or insulin resistance plus two other abnormalities (high blood pressure, 
dyslipidemia, obesity, and microalbuminuria) (WHO, 1999). In the same year the 
European Group for the study of Insulin Resistance (EGIR) defined insulin resistance 
syndrome as fasting hyperinsulinemia plus two additional abnormalities (high blood 
pressure, dyslipidemia, large waist circumference and high fasting blood glucose) 
(Balkau and Charles, 1999). In 2001, the National Cholesterol Education Program- 
Adult Treatment Panel III (NCEP-ATP III) suggested the presence of any three of the 
following for the diagnosis of metabolic syndrome: abdominal obesity, atherogenic 
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dyslipidemia, elevated blood pressure, insulin resistance (with or without glucose 
intolerance), and prothrombotic and proinflammatory states (“Executive Summary of 
The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel 
on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III).,” 2001). 
The American College of Endocrinology (ACE) /American Association of 
Clinical Endocrinologists (AACE) statement in 2003 suggested that the diagnosis of 
insulin resistance syndrome or metabolic syndrome should rely on clinical judgment and 
proposed the presence of at least one of the following factors: diagnosis of 
cardiovascular diseases, hypertension, family history of type 2 diabetes mellitus and 
hypertension, or cardiovascular diseases, non-Caucasian ethnicity, sedentary lifestyle, 
high body mass index and/or large waist circumference and age above 40 years, and at 
least two of the following criteria: high triglycerides (TG), low high-density lipoprotein-
cholesterol (HDL-C), high blood pressure, high fasting blood glucose or postglucose 
challenge 140-200 mg/dl (Einhorn et al., 2003). 
In spite of little difference in the prognostic implications when applying different 
definitions of metabolic syndrome (Hanley et al., 2005), the existence of numerous 
definitions of metabolic syndrome has led to a confusion, which made the International 
Diabetes Federation (IDF) to gather experts from different parts of the world to 
formulate a single definition, with generally accepted diagnostic criteria, that is easy to 
use in clinical practice. Moreover, because the problem of metabolic syndrome has 
reached at an alarming rate (estimated to be around 20–25% of the population) (Dunstan 
et al., 2002), the IDF suggested more strict criteria for the diagnosis of metabolic 
16 
 
syndrome. The IDF suggested five criteria for the diagnosis of metabolic syndrome and 
made abdominal obesity (large waist circumference) necessary plus the presence of any 
two of the following: high TG, low HDL-C, high blood pressure, high fasting blood 
glucose (Alberti et al., 2006). Table 2.1 summarizes selected definitions of metabolic 
syndrome established by different organizations and experts. 
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Table 2.1 Selected definitions for metabolic syndrome 
  IDF ACE/AACE NCEP-ATP III WHO EGIR 
       
Year  2006 2003 2001 1999 1999 
       
Mandatory criterion  Central obesity IGT or IFG None Insulin resistance Hyperinsulinemia 
       
Obesity 
 
Central obesity 
(Large WC)* 
BMI≥25 kg/m2 
Central obesity 
(Large WC) 
Obesity (Large WHR) or 
BMI > 30 kg/m2 
Central obesity 
(Large WC) 
Male ≥ 94 cm  ≥102 cm > 0.9cm ≥ 94 cm 
Female ≥ 80 cm  ≥88 cm > 0.85 ≥ 80 cm 
Serum Triglycerides  ≥150 mg/dl ≥150 mg/dl ≥150 mg/dl ≥150 mg/dl ≥ 177 mg/dl 
       
Serum HDL-
Cholesterol 
Male <40 mg/dl <40 mg/dl <40 mg/dl ≤35 mg/dl < 39 mg/dl 
Female <50mg/dl <50mg/dl <50mg/dl ≤39 mg/dl < 39 mg/dl 
       
Blood Pressure 
Systolic ≥130 mmHg ≥130 mmHg ≥130 mmHg ≥140 mmHg ≥140 mmHg 
Diastolic ≥85 mmHg ≥85 mmHg ≥85 mmHg ≥90 mmHg ≥90 mmHg 
       
Fasting Glucose  ≥100 mg/dl >110 mg/dl ≥110 mg/dl DM, IGT, IFG or IR ≥110 mg/dl 
       
Microalbuminuria -- -- -- -- 
Urinary albumin excretion 
ratio ≥20 µg/min Or 
-- 
Albumin: creatinine ratio 
≥30mg/g 
* Ethnicity-specific values 
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2.1.2 Prevalence of metabolic syndrome 
Globally, the prevalence of metabolic syndrome varies from less than 10% to 
more than 84%. Such variations are related to the region, sex, age, race and ethnicity, 
and whether the population from the urban or rural area, in addition to metabolic 
syndrome definition used in the study (Kolovou et al., 2007). The prevalence of 
metabolic syndrome in the states of Gulf Cooperation Council is about 10-15% 
greater than in most industrialized countries, with generally lower prevalence rates 
for men (Mabry et al., 2010). A report of the United Arab Emirates national survey 
showed that the prevalence of metabolic syndrome was 39.6% and 40.5% using the 
NCEP and IDF definition respectively. Also, showed that the occurrence of 
metabolic syndrome was associated with increasing age and female gender (Malik 
and Razig, 2008). In another study in the United Arab Emirates which recruited 
overweight and obese subjects aged 18–50 years, the prevalence of metabolic 
syndrome was 40.5% (Al-Sarraj et al., 2010). In a school-based study on Emirati 
adolescents (12-18 years), the prevalence of metabolic syndrome was 13% and boys 
(21%) were more likely to have metabolic syndrome than girls (4%) (Mehairi et al., 
2013). Most recent study elucidated that the prevalence of metabolic syndrome was 
around 22% among rural adults from the United Arab Emirates (Luz Espina, 2014). 
2.1.3 Pathophysiology of metabolic syndrome 
Metabolic syndrome is a complex condition and the mechanisms underlying 
metabolic syndrome are incompletely understood (Eckel et al., 2005) and its causes 
were described to be multi-factorial. Yet, the interaction of genetic and 
environmental factors together with dietary habits could play a role in metabolic 
syndrome development. Abdominal obesity and insulin resistance were proposed to 
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be the most accepted underlying factors that contribute to the pathophysiology of the 
syndrome (Grundy et al., 2005; Reaven, 1988; Wassink et al., 2007). However, 
additional factors like inflammation (Esposito and Giugliano, 2004), endothelial 
dysfunction (Pinkney et al., 1997) and unbalanced autonomic nervous system 
stimulation (Kreier et al., 2003) may also be involved. 
2.1.3 (a) Obesity and adipose tissue 
The American Medical Association (2013) stated that obesity should be 
considered as a chronic medical disease state (AMA, 2013), which is characterized 
by excessive accumulation of adipose tissue (WHO, 2016). There is a continues 
global increase in the incidence of overweight and obesity among adults with more 
than one billion adults are overweight and 500 million are obese (World Obesity 
Organization, n.d.). Recent reports on the prevalence of overweight and obesity are 
shocking in Arabian Gulf states especially in Bahrain, Qatar, Kuwait, and Saudi 
Arabia where more than two-thirds of adults and adolescents are overweight or obese 
(Ng et al., 2011). In a survey released by Zurich International Life, 47.5% and 13% 
of UAE residents were overweight and obese respectively (Geranpayeh, 2015), with 
more than 50% had central obesity (Hajat et al., 2012). 
In order to understand the pathophysiology of metabolic syndrome, one 
should have an overview of the adipose tissue structure and functions. Adipose tissue 
is a loose connective tissue that consists of different cell types. The main cells are 
adipocytes (fat cells), fibroblasts (fiber-forming cells), macrophages (type M1 and 
M2), endothelial cells and blood cells which are embedded in a matrix of connective 
tissue (Cinti, 2009). There are two main histological types of adipose tissue; brown 
adipose tissue and white adipose tissue. The brown adipose tissue is well 
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vascularized with many mitochondria and its function is to generate heat and 
therefore it maintains body temperature (Cannon and Nedergaard, 2004). While, 
white adipose tissue represents the main part of the adipose tissue, which is poorly 
vascularized with fewer mitochondria and it is the site of accumulation of lipid 
(mainly triglycerides). Recent research showed that white adipose tissue is not just a 
silent structure that passively acts as a storage site for excess energy, but it is a 
dynamic endocrine organ (Scherer, 2006) with multiple metabolic roles in regulating 
whole-body physiology. The white adipose tissue is subdivided into two parts: 
visceral adipose tissue and subcutaneous adipose tissue. They are different in their 
location, cellular, molecular and physiological aspects. As compared to subcutaneous 
adipose tissue, visceral adipose tissue is found mainly in the omentum and 
mesentery, and directly connected to the liver via the portal circulation. The visceral 
adipose tissue is more cellular, and has rich blood and nerve supply, with many 
inflammatory and immune cells. Its adipocytes are metabolically more active, with 
higher sensitivity to lipolysis and are more insulin resistant compared to the 
adipocytes of subcutaneous adipose tissue. Cells of visceral adipose tissue secrete 
biologically active molecules known as adipokines (produced by the adipocytes) and 
cytokines (produced by the macrophages) and are collectively called adipocytokines. 
Macrophage type M1 produces proinflammatory cytokines like TNF-α and IL-6, 
while type M2 produces anti-inflammatory cytokines such as IL-10 (Mills, 2012). In 
obesity, there is domination of M1 over M2 i.e. more production of proinflammatory 
than anti-inflammatory cytokines. It has been suggested that these cytokines, which 
are secreted by the adipose tissue in obese individuals, could contribute to the high 
inflammatory (C-reactive protein; CRP) proteins secretion by the liver and results in 
the state of chronic low-grade inflammation (Maachi et al., 2004). In 1993, two 
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independent groups of researchers reported that TNF-α, which is produced by the 
adipose tissue  and overproduced by enlarged adipose tissue, was able to induce 
insulin resistance (Feinstein et al., 1993; Hotamisligil et al., 1993) via its local and 
possibly systemic effects on metabolism. 
The concept of adipose tissue as a dynamic endocrine organ capable of 
producing other bioactive molecules quickly broadens beyond TNF-α to include a 
long list of adipocytokines. Many of these adipocytokines play a role in 
inflammation and may affect insulin action with subsequent development of insulin 
resistance. These include leptin (Zhang et al., 1994), adiponectin (Scherer et al., 
1995), IL-6 (Fried et al., 1998), resistin (Steppan et al., 2001), PAI-1 (Shimomura et 
al., 1996), angiotensinogen, visfatin (Fukuhara et al., 2005) and others. It has been 
suggested that inflammation is an important contributor in the pathophysiology of 
hypertension and cardiovascular diseases (Savoia and Schiffrin, 2006) and also found 
to play a role in the pathogenesis of type 2 diabetes mellitus (Spranger et al., 2003).  
2.1.3 (b) Autonomic nervous system overactivity 
During the last decade, overactivity of the sympathetic nervous system was 
noticed in obese individuals and in those with central obesity in particular (Grassi et 
al., 2004). This excessive sympathetic system stimulation could be due to 
dysfunction of the arterial baroreceptors, insulin resistance, and increase levels of 
adipokines such as angiotensin II and leptin. The effects of the sympathetic nervous 
system on the regulation of blood pressure and cardiovascular system functions are 
well acknowledged. A recent study also demonstrated the association of sympathetic 
activity with elevated cholesterol levels, which may play a role in the development of 
cardiovascular disease (Lambert et al., 2013). However, its effects on energy 
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homeostasis and body metabolism are less well appreciated. Therefore, all these 
findings, which are summarized in Figure 2.1, on the role of the activated 
sympathetic nervous system in the development of metabolic syndrome should be 
considered (Thorp and Schlaich, 2015). 
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Figure 2.1 Role of the sympathetic nervous system in the development of metabolic syndrome 
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2.2 Adiponectin 
Adiponectin, which is also known as Acrp30 (Scherer et al., 1995), AdipoQ 
(Huet al., 1996), apM1 (Maeda et al., 1996) and GBP28 (Nakano et al., 1996)is the 
most abundant and relatively new adipocytokine that is exclusively secreted by the 
adipocytes (Scherer et al., 1995). A few years ago, two adiponectin receptors were 
identified; adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2). 
AdipoR1 is plentifully expressed in the skeletal muscle, while AdipoR2 is primarily 
expressed in the liver (Yamauchi et al., 2003). Adiponectin exhibits insulin-
sensitizing, fat-burning (Yamauchi et al., 2001), anti-atherogenic (Shimada et al., 
2004) and anti-inflammatory properties (Ouchi et al., 2003). It is distinct from other 
adipocytokines in that the production and circulating level of adiponectin are 
decreased with obesity. Hence, low adiponectin levels are commonly reported in 
obesity and related disorders (Lara-Castroet al., 2006) such as type 2 diabetes 
mellitus (Hotta et al., 2000) and certain types of cancer (van Kruijsdijk et al., 2009). 
In addition, low adiponectin levels in healthy individuals could be linked to increased 
risk of cardiovascular events (Pischon et al., 2004). Serum levels of adiponectin have 
been reported to be affected by genetic factors (Yamamoto et al., 2002), ethnicity 
(Martin et al., 2008; Pereira et al., 2011), dietary fat content (Barnea et al., 2006), 
exercise(Lee et al., 2013) and drugs like thiazolidinediones (Li et al., 2010) and 
statins (von Eynatten et al., 2009). Adiponectin has been reported to play a protective 
role in the development of metabolic syndrome (Calton et al., 2013; Hunget al., 
2008; Koh et al., 2010). Thus, serum adiponectin level has been expected to serve as 
a valuable biomarker to predict the development of metabolic syndrome. The 
possible role of adiponectin the development of metabolic syndrome is summarized 
in Figure 2.2. 
